Please login to the form below

Not currently logged in
Email:
Password:

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

GSK wins approval for skin cancer drug Mekinist in EU

GSK wins approval for skin cancer drug Mekinist in EU

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Latest news

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Interview: Bruno Strigini, MSD Interview: Bruno Strigini, MSD

    Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line

  • Pharma deals during February 2014 Pharma deals during February 2014

    Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). MK-3475 was

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....